Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

733

Tables (1-6)

148

Sum=988

Publishing Process of This Article

Item

Count

Browse

Download

323

Sum=397

Jan 6, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68

Table 3 Coagulation status in the two groups

Data are presented as n (%).

Citation: Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
URL: https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.68